210 related articles for article (PubMed ID: 24412083)
1. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors.
Braga Lda C; Silva LM; Piedade JB; Traiman P; da Silva Filho AL
Arch Gynecol Obstet; 2014 May; 289(5):1061-9. PubMed ID: 24190693
[TBL] [Abstract][Full Text] [Related]
3. TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.
Braga Lda C; Alvares da Silva Ramos AP; Traiman P; Silva LM; Lopes da Silva-Filho A
Gynecol Oncol; 2012 Aug; 126(2):268-73. PubMed ID: 22555108
[TBL] [Abstract][Full Text] [Related]
4. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
[TBL] [Abstract][Full Text] [Related]
5. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
6. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer.
Winham SJ; Armasu SM; Cicek MS; Larson MC; Cunningham JM; Kalli KR; Fridley BL; Goode EL
Genet Epidemiol; 2014 Jul; 38(5):457-66. PubMed ID: 24853948
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
[TBL] [Abstract][Full Text] [Related]
9. Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer.
Chung VY; Tan TZ; Huang RL; Lai HC; Huang RY
Gene; 2017 Nov; 635():9-15. PubMed ID: 28887161
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
[TBL] [Abstract][Full Text] [Related]
11. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
13. A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.
Guerrero K; Wang Z; Bachvarova M; Gregoire J; Renaud MC; Plante M; Bachvarov D
Gynecol Oncol; 2012 Jun; 125(3):720-6. PubMed ID: 22446619
[TBL] [Abstract][Full Text] [Related]
14. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
[TBL] [Abstract][Full Text] [Related]
15. FBXW12, a novel F box protein-encoding gene, is deleted or methylated in some cases of epithelial ovarian cancer.
De La Chesnaye E; Méndez JP; López-Romero R; De Los Angeles Romero-Tlalolini M; Vergara MD; Salcedo M; Ojeda SR
Int J Clin Exp Pathol; 2015; 8(9):10192-203. PubMed ID: 26617728
[TBL] [Abstract][Full Text] [Related]
16. Synaptotagmin-like protein 2 gene promotes the metastatic potential in ovarian cancer.
Sung HY; Han J; Ju W; Ahn JH
Oncol Rep; 2016 Jul; 36(1):535-41. PubMed ID: 27220283
[TBL] [Abstract][Full Text] [Related]
17. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
[TBL] [Abstract][Full Text] [Related]
18. Frequent inactivation of hSRBC in ovarian cancers by promoter CpG island hypermethylation.
Tong SY; Ki KD; Lee JM; Kang MJ; Ha TK; Chung SI; Chi SG; Lee SK
Acta Obstet Gynecol Scand; 2010 May; 89(5):629-35. PubMed ID: 20423276
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma.
Bhagat R; Kumar SS; Vaderhobli S; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2014 Sep; 35(9):9069-78. PubMed ID: 24913706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
